JP2024509917A5 - - Google Patents
Info
- Publication number
- JP2024509917A5 JP2024509917A5 JP2023555231A JP2023555231A JP2024509917A5 JP 2024509917 A5 JP2024509917 A5 JP 2024509917A5 JP 2023555231 A JP2023555231 A JP 2023555231A JP 2023555231 A JP2023555231 A JP 2023555231A JP 2024509917 A5 JP2024509917 A5 JP 2024509917A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- pharmaceutical composition
- antigen
- orthogonal
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158671P | 2021-03-09 | 2021-03-09 | |
| US63/158,671 | 2021-03-09 | ||
| PCT/US2022/019479 WO2022192346A1 (en) | 2021-03-09 | 2022-03-09 | Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509917A JP2024509917A (ja) | 2024-03-05 |
| JP2024509917A5 true JP2024509917A5 (https=) | 2025-03-12 |
Family
ID=83227027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555231A Pending JP2024509917A (ja) | 2021-03-09 | 2022-03-09 | 腫瘍溶解性ウイルスによる直交性ｉｌ－２の送達を用いた、固形腫瘍におけるｔ細胞の選択的刺激方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240299541A1 (https=) |
| EP (1) | EP4305054A4 (https=) |
| JP (1) | JP2024509917A (https=) |
| CN (1) | CN117377682A (https=) |
| WO (1) | WO2022192346A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| EP4402160A4 (en) * | 2021-09-17 | 2025-11-19 | Univ Pennsylvania | CHIMERIC ANTIGENIC RECEPTORS COMPRISING AN INTERLEUKIN-9 RECEPTOR SIGNALING DOMAIN |
| WO2024015988A1 (en) * | 2022-07-15 | 2024-01-18 | The Regents Of The University Of California | Il-9r signaling compositions and method |
| CN120225568A (zh) * | 2022-12-27 | 2025-06-27 | 广州瑞风生物科技有限公司 | 一种融合蛋白及其应用 |
| WO2025085721A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Chimeric receptors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117659160A (zh) * | 2015-09-11 | 2024-03-08 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
| AU2019215031C1 (en) * | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2020163634A1 (en) * | 2019-02-08 | 2020-08-13 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric cytokine receptors |
| CA3179414A1 (en) * | 2020-04-06 | 2021-10-14 | Synthekine, Inc. | Human immune cells genomically modified to express orthogonal receptors |
-
2022
- 2022-03-09 WO PCT/US2022/019479 patent/WO2022192346A1/en not_active Ceased
- 2022-03-09 EP EP22767860.4A patent/EP4305054A4/en active Pending
- 2022-03-09 CN CN202280033752.0A patent/CN117377682A/zh active Pending
- 2022-03-09 JP JP2023555231A patent/JP2024509917A/ja active Pending
- 2022-03-09 US US18/549,503 patent/US20240299541A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024509917A5 (https=) | ||
| Klein et al. | The present and future of bispecific antibodies for cancer therapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JP6909844B2 (ja) | 細胞 | |
| JP7335272B2 (ja) | キメラ抗原受容体 | |
| JP2022548778A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| JP2024534471A5 (https=) | ||
| JP2022542543A5 (https=) | ||
| Hoseini et al. | Acute myeloid leukemia targets for bispecific antibodies | |
| JP2020530989A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| JP2021519580A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2018529376A5 (https=) | ||
| TW201920653A (zh) | 調節細胞表達的生物活性之結合分子 | |
| JP2024534417A5 (https=) | ||
| JP2017532014A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| JP2021536265A5 (https=) | ||
| JP2022507295A5 (https=) | ||
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2018521628A5 (https=) | ||
| Liu et al. | Structures of immune checkpoints: an overview on the CD28-B7 family | |
| JP2022527081A5 (https=) |